Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal matter transplant
- Development stage
- Unknown
- Lead developer
- Rutgers University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Autologous fecal matter transplant (FMT) is an investigational microbiome-restoration therapy developed by Rutgers, The State University of New Jersey. It is specifically designed to mitigate gut microbiome dysbiosis in infants and toddlers who have undergone antibiotic treatment. The procedure involves the collection and preservation of the patient's own fecal microbiota prior to antibiotic exposure, which is subsequently reintroduced—often via oral administration in milk or formula—to rapidly restore the intestinal flora to its baseline composition. This approach aims to prevent the long-term health complications associated with early-life microbiome disruption, such as obesity, asthma, and metabolic disorders, by bypassing the slow and often incomplete natural recovery process.
- Other names
- autologous fecal microbiota transplantationautologous FMTFMT
Beyond the preview
Go deeper on autologous fecal matter transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal matter transplant.